Micron raises third-quarter revenue forecast

(Reuters) - Micron Technology Inc (NASDAQ: MU) raised its revenue forecast for the third quarter on Wednesday to a range of $5.2 billion to $5.4 billion from $4.6 billion to $5.2 billion, sending its shares about 3% higher.

The memory chipmaker said in a regulatory filing https://www.sec.gov/ix?doc=/Archives/edgar/data/723125/000072312520000053/mu-20200527.htm that it expected adjusted earnings between 75 cents per share and 80 cents per share.

"We had strong demand from our customers – notably in the data center space – and that demand has been driven mostly due to the work-from-home economy, the increased load on the server infrastructure because of everyone working from home, entertaining from home," Sumit Sadana, Micron's chief business officer, told Reuters in an interview.

Sadana said Micron also saw increased sales of server chips to retailers expanding their e-commerce operations to handle extra demand while many physical retail locations were shuttered during the novel coronavirus pandemic. Micron also saw increased sales of laptop memory chips for work and education at home.

Analysts had expected a revenue of $4.93 billion and adjusted earnings of 56 cents per share, according to IBES data from Refinitiv.

South Korean chip stocks rose on Thursday on Micron's third-quarter revenue guidance.

Shares of Samsung Electronics Co Ltd <005930.KS>, the world's biggest memory chip maker, rose as much as 2.6% to 51,2000 won, while domestic rival SK Hynix <000660.KS> gained 4.4% to 85,000 won by 0109 GMT. The benchmark KOSPI market <.KS11> was trading up 0.9%.

(Reporting by Ayanti Bera in Bengaluru and Stephen Nellis in San Francisco; additional reporting by Heekyong Yang in Seoul; editing by Uttaresh.V and Sonya Hepinstall)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rice Robotics Hong Kong signs non-binding cooperation deal with Vengine
• Workday names Sarah Kennedy Ellis as chief marketing officer
• CervoMed nfvPPA trial data to be presented at ISFTD meeting